Seung Hyeon Weon,Yuhyeon Na,Jiwoo Han,Jeong Woo Lee,Hyung Joo Kim,Saerom Park,Sang Hyun Lee
Abstract:In this study, cellulose/Fe3O4 hydrogel microbeads were prepared through the sol–gel transition of a solvent-in-oil emulsion using various cellulose-dissolving solvents and soybean oil without surfactants. Particularly, 40% tetrabutylammonium hydroxide (TBAH) and 40% tetrabutylphosphonium hydroxide (TBPH) dissolved cellulose at room temperature and effectively dispersed Fe3O4, forming cellulose/Fe3O4 microbeads with an average diameter of ~15 μm. Additionally, these solvents co-dissolved cellulose and silk, allowing for the manufacture of cellulose/silk/Fe3O4 hydrogel microbeads with altered surface characteristics. Owing to the negatively charged surface characteristics, the adsorption capacity of the cellulose/silk/Fe3O4 microbeads for the cationic dye crystal violet was >10 times higher than that of the cellulose/Fe3O4 microbeads. When prepared with TBAH, the initial adsorption rate of bovine serum albumin (BSA) on the cellulose/silk/Fe3O4 microbeads was 18.1 times higher than that on the cellulose/Fe3O4 microbeads. When preparing TBPH, the equilibrium adsorption capacity of the cellulose/silk/Fe3O4 microbeads for BSA (1.6 g/g) was 8.5 times higher than that of the cellulose/Fe3O4 microbeads. The pH-dependent BSA release from the cellulose/silk/Fe3O4 microbeads prepared with TBPH revealed 6.1-fold slower initial desorption rates and 5.2-fold lower desorption amounts at pH 2.2 than those at pH 7.4. Cytotoxicity tests on the cellulose and cellulose/silk composites regenerated with TBAH and TBPH yielded nontoxic results. Therefore, cellulose/silk/Fe3O4 microbeads are considered suitable pH-responsive supports for orally administered protein pharmaceuticals.
What problem does this paper attempt to address?
The problem this paper attempts to address is the differential diagnosis between Parkinson’s Disease (PD) and Atypical Parkinsonian Syndromes (APS). Specifically, the authors review relevant literature from the past 10 years to explore the potential diagnostic value of Optical Coherence Tomography (OCT) in assessing retinal parameters in patients with Parkinsonian syndromes, particularly how to effectively distinguish between different types of Parkinsonian syndromes such as Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD), and Lewy Body Dementia (LBD).
### Background
Parkinsonian syndromes are a clinically diverse group of disorders characterized primarily by bradykinesia, rigidity, resting tremor, and postural instability. Although approximately 80% of Parkinsonian syndrome cases are attributed to idiopathic Parkinson’s Disease, other non-PD disorders, known as Parkinson-plus syndromes, can exhibit similar clinical features. These atypical Parkinsonian syndromes include PSP, MSA, CBD, and LBD. Parkinson’s Disease is one of the most common neurodegenerative diseases among the elderly, with its incidence increasing globally. However, distinguishing PD from atypical Parkinsonian syndromes remains a significant challenge, especially in the early stages of the disease, with misdiagnosis rates as high as 10% to 20%.
### Objective
Given the aging global population and the increasing burden of PD, there is an urgent need for rapid and accurate differentiation between PD and atypical Parkinsonian syndromes. OCT, as a non-invasive, repeatable, and cost-effective technique, can visualize retinal structures in real-time, providing valuable information on subtle changes in retinal morphology. The researchers aim to review relevant literature from the past 10 years to explore the application of OCT in patients with Parkinsonian syndromes, particularly its potential value in differential diagnosis.
### Methods
The researchers conducted a systematic review and literature search using the PRISMA guidelines, retrieving relevant studies published between April 13, 2012, and January 23, 2023, from two databases (MEDLINE and Scopus). Keywords included “Optical Coherence Tomography” (OCT) and “Parkinsonian syndromes,” “Atypical Parkinsonian syndromes,” “Parkinson’s Disease,” “Progressive Supranuclear Palsy,” “Corticobasal Degeneration,” “Multiple System Atrophy,” and “Lewy Body Dementia.” Ultimately, 7 studies met the inclusion criteria and were categorized into three groups based on the nature of the disease entities compared.
### Results
The study found that OCT has certain potential in assessing retinal parameters in patients with Parkinsonian syndromes. For example, the retinal nerve fiber layer (RNFL) thickness in PSP patients was significantly reduced, while the retinal parameters in PD patients showed no significant difference compared to healthy controls. Additionally, specific patterns of retinal layer changes may help distinguish between different types of Parkinsonian syndromes. For instance, the ratio of the outer nuclear layer (ONL) to the outer plexiform layer (OPL) in PSP patients was significantly different from that in PD patients, which could be an important indicator for differential diagnosis.
### Discussion
Although OCT shows some potential in differentiating PD from atypical Parkinsonian syndromes, reliable OCT biomarkers for clinical practice have not yet been developed. Future research needs to further validate the application of OCT in this field to improve the diagnostic accuracy of Parkinsonian syndromes.